KP Tissue Earnings Call Highlights Growth And Expansion

KP Tissue ((TSE:KPT)) has held its Q4 earnings call. Read on for the main highlights of the call.

KP Tissue’s latest earnings call struck a confident tone, with management emphasizing strong operational momentum, solid profitability gains and healthier balance sheet metrics. While they acknowledged cost inflation, pulp price volatility and higher planned capital spending, executives argued that robust EBITDA growth, market-share gains and disciplined execution leave the company well positioned for the next phase of expansion.

Adjusted EBITDA Growth and Margin Expansion

KP Tissue delivered Q4 adjusted EBITDA of $84.2 million, a 26% increase versus last year and the second straight quarter with a run-rate above $80 million. The adjusted EBITDA margin rose to 15.0% from 12.4%, underscoring that recent pricing, mix improvements and cost initiatives are now translating into structurally higher profitability.

Revenue Growth Accelerates at the Top Line

Consolidated Q4 revenue reached $560.1 million, up nearly 4% year over year, supported by gains across key categories and geographies. For the full fiscal year, management highlighted revenue growth of 7.5%, signaling that the business is expanding at a healthy pace even as certain end markets remain uneven.

Net Income Swings Back into Positive Territory

Q4 net income improved sharply to $23.4 million compared with a net loss of $13.7 million in the prior-year quarter. The turnaround was driven by higher adjusted EBITDA and a sizable foreign exchange gain, although management reminded investors that part of this benefit is non-operational and may not repeat.

Canada and U.S. Markets Deliver Broad-Based Gains

In Q4, Canadian revenue grew 5.1%, adding roughly $15 million, while U.S. sales climbed 2.2%, or about $5.5 million, against a tough comparison. On a full-year basis, the U.S. business posted an 8.2% growth rate and was described as the company’s primary growth engine, highlighting the strategic importance of that market.

Consumer and AFH Segments Both Strengthen

Consumer revenue rose 4.3% to $472.3 million, with segment adjusted EBITDA of $78.1 million and a margin of 16.5%, roughly two points higher than last year. The Away-From-Home business delivered more modest 1% revenue growth to $87.8 million, but adjusted EBITDA more than doubled to $9.7 million, lifting margin to about 11%.

Market Share Wins in Core Canadian Categories

KP Tissue continued to gain ground in Canada, with facial tissue share up 130 basis points to 46.3% over the latest 52-week period. Paper towel market share also climbed 130 basis points to 25.3%, and bathroom tissue showed incremental gains, signaling successful brand support and execution at the shelf.

Operational Execution and Safety Improvements

Management highlighted positive production rates across both paper machines and converting operations, pointing to efficiency gains in the network. The Memphis converting line remains on track for startup in early Q2 2026, Sherbrooke in-sourcing is improving AFH margins, and 2025 marked record safety results across manufacturing sites.

Balance Sheet, Liquidity and Leverage Trends

Cash rose to $196.1 million from $149.1 million at the end of Q3, while long-term debt edged down by $9.4 million to $1.741 billion. Net debt fell by $55.7 million and the leverage ratio improved to 3.1 times from 3.4 times, giving the company more flexibility as it steps up strategic capital investments.

Sequential Softness in Revenue and EBITDA

Despite strong year-over-year numbers, Q4 revenue slipped slightly versus Q3, down $1 million or 0.2%, with U.S. sales off $6 million, or 2.3%, quarter over quarter. Adjusted EBITDA eased by $1.5 million, or 1.8%, sequentially, reflecting a softer quarter-on-quarter trajectory that management is monitoring.

Operating Cost Inflation Pressures Margins

The quarter-on-quarter EBITDA decline was partly driven by higher SG&A, freight and warehousing costs, as well as stepped-up marketing spend and increased manufacturing overhead. These rising expenses offset some of the benefit from lower pulp prices and highlight the ongoing need for cost discipline as the company invests for growth.

Pulp Price Volatility and 2026 Cost Risk

Pulp prices moved within a relatively wide range in Q4, with quarter-over-quarter shifts between minus 6.6% and plus 3.3% and year-over-year declines for both NBSK and BEK grades. Management cautioned that industry expectations point to higher pulp prices in 2026, which could put renewed pressure on margins if not countered by pricing or productivity gains.

Higher Capital Spending and Short-Term Leverage Bump

Capital expenditures are projected to rise to $100–$120 million in 2026 from $78 million in 2025, driven by the new converting line and other strategic projects. Executives indicated that leverage could temporarily move above 4 times during construction of a new TAD project before trending lower again as the asset ramps and cash generation improves.

Non-Operating Items Boost Net Income

Management emphasized that Q4 net income benefited materially from a favorable foreign exchange gain of $29.7 million, which is not part of the core operating story. This uplift was partly offset by higher income attributable to noncontrolling interests, rising income taxes and increased interest and finance costs, tempering the underlying earnings improvement.

AFH Segment Volatility and Macro Uncertainty

While AFH results looked strong on a year-over-year basis, adjusted EBITDA fell $0.7 million sequentially and margin slipped versus Q3, pointing to some near-term variability. Executives flagged ongoing economic uncertainty in the AFH market and suggested that demand and pricing dynamics in that segment require close monitoring.

Guidance and Strategic Outlook

For Q1 2026, management expects adjusted EBITDA to remain in line with Q4 levels, keeping the consolidated margin around 15% with similar consumer and AFH profitability. They raised 2026 CapEx guidance, confirmed the Memphis line’s early Q2 2026 start, outlined a planned Western U.S. TAD plant for 2028 and reiterated a flexible pricing strategy to respond to potential input cost increases.

KP Tissue’s earnings call painted a picture of a company that is growing, improving margins and strengthening its balance sheet while laying the groundwork for meaningful capacity expansion. Investors will need to weigh the benefits of sustained EBITDA momentum and market-share gains against near-term risks from higher spending, pulp volatility and leverage that may briefly tick higher as new projects come online.